로딩 중…
지수 로딩 중…
Faeth Therapeutics Inc. Common Stock
FTH· NASDAQ· Health Care
$26.03+1.64%
2026-10-09
Financials
Valuation Metrics
Faeth Therapeutics Inc. Common Stock's Market Cap is $673M. At end of 2025 it was $13M. Ranked #2658 of 3,115 in US market (top 85%), #1140 of 1,464 on NASDAQ (top 78%) by Market Cap.
Investment Metrics(as of 2026-10-09)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $673M | US#2,658/3,115 |
| Revenue | $0.00 | US#2,861/3,115 |
| Net Income | $-21M | US—/3,115 |
| Total Assets | $23M | US#3,084/3,115 |
| Net Assets | $19M | US#2,890/3,115 |
| Employees | 29 | US#2,739/3,115 |
| Value | ||
| P/B | 36.18x | US#2,862/3,115 |
| FCF Yield | -3.04% | US—/3,115 |
| Profitability | ||
| ROE | -113.41% | US#2,798/3,115 |
| ROA | -92.07% | US#3,052/3,115 |
| Financial Health | ||
| Debt Ratio | 23.18% | US#259/3,115 |
| Total Debt | $2M | US#2,966/3,115 |
| FCF | $-20M | US#2,429/3,115 |
| Cash | $9M | US#2,986/3,115 |
| Current Ratio | 5.06x | US#462/3,115 |
| Performance | ||
| 1Y Return | 124.59% | US#129/3,115 |
| 1M Return | -27.93% | US#3,072/3,115 |
| From 52W High | -38.23% | US#2,426/3,115 |
| 1Y MDD | -69.23% | US#2,937/3,115 |
| Trading | ||
| Volume | 196,473 shares | US#2,332/3,115 |
| Trading Value | $5M | US#2,406/3,115 |
| Per Share | ||
| EPS | $-0.82 | US—/3,115 |
| BPS | $0.72 | US#2,728/3,115 |
Company Info
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]